Friday। 20 November। 2026
আগামীর সময়
Friday। 20 November। 2026
Agamir Somoy
  • Latest
  • Bangladesh
  • Business
  • Chattogram
  • District
  • World
  • Environment
  • Entertainment
  • Sports
  • Feature
  • OP-ED
  • Misc
  • Success Story
  • Religion
BN
  • Latest
  • Bangladesh
  • Business
  • Chattogram
  • District
  • World
  • Environment
  • Entertainment
  • Sports
  • Feature
  • OP-ED
  • Misc
  • BN
লোড হচ্ছে…

Chief Editor & Publisher: Abdus Sattar Miazi

Editor: Mustafa Mamun

Agamir Somoy English Logo
About UsContactTerms of ServicePrivacy PolicyTeam

EDB Trade Centre (Level-6 &7) 93 Kazi Nazrul Islam Avenue Karwanbazar, Dhaka-1215.

Contact: +880 9666 771010

Advertise: +880 1755 651164

[email protected]

© 2026 | Dainik Agamir Somoy. All rights reserved.

আগামীর সময় World

New pancreatic cancer drug raises hopes

International Desk
agamir somoy
Published: 20 November 2026, 20:26
শেয়ার করুন:
New pancreatic cancer drug raises hopes

Collected Photo

Experts are hopeful about a breakthrough in the treatment of pancreatic cancer, a disease widely known for being highly deadly and difficult to cure. Their hopes are centered on a tablet that patients can take daily. The drug could shrink tumors in some patients and may even eliminate them completely.

Researchers have described the development as one of the biggest advances in cancer treatment in recent decades. In an early-stage clinical trial, patients received a drug called daraxonrasib alongside chemotherapy. Follow-up scans found no detectable signs of cancer in one out of every 12 patients.

In a recent study involving 61 patients with advanced pancreatic cancer that had spread to other parts of the body, tumor growth was halted in almost all cases.

However, doctors have stressed that it remains unclear how long the drug can control the disease. It should not be considered a complete cure or a permanent solution.

Cancer Research UK has described the development as the biggest advance in pancreatic cancer treatment in decades.

Dr. Sam Godfrey of the charity said the results were incredibly encouraging. He said the new drug had found a way to target a disease against which no drugs had previously been effective.

He noted that after a long wait, progress was finally being made in the treatment of pancreatic cancer.

Treating pancreatic cancer is extremely difficult. Among all common cancers in the United Kingdom, pancreatic cancer has the lowest survival rate.

Although chemotherapy can shrink tumors to some extent, the cancer often returns. Most patients with advanced-stage pancreatic cancer survive for only a few months.

Doctors hope that even if the new treatment cannot stop the cancer permanently, it could help patients live longer.

Patients in the trial were monitored for an average of 18 months. During this period, the cancer did not return in some patients.

Further long-term research is needed to determine whether these cancers can be brought into temporary or sustained remission and how long such remission might last.

The Phase 1/2 trial found that tumor growth was halted in 90 percent of patients. Tumors shrank or disappeared in slightly more than 60 percent of patients. In around 8 percent of cases, or approximately one in every 12 patients, tumors were no longer detectable on CT scans.

Dr. Wonki Park of Memorial Sloan Kettering Cancer Center in the United States, who was involved in the trial, said the results so far were extremely encouraging.

Daraxonrasib is an approved targeted inhibitor treatment in the United States. Most pancreatic cancers have specific genetic changes or mutations that drive tumor growth. The drug works by blocking these mutations.

Similar mutations can also occur in several dozen other types of cancer, including lung and ovarian cancer. This means the drug could potentially benefit many more patients.

Dr. Godfrey said he was hopeful that the early success they were beginning to see in pancreatic cancer could also be applied to other types of cancer.

Pancreatic cancer accounts for around 3 percent of all cancer cases in the United States. However, it is responsible for approximately 8 percent of all cancer-related deaths, claiming around 53,000 lives every year.

According to Cancer Research UK, around 11,500 people are diagnosed with pancreatic cancer in Britain every year, while approximately 10,200 die from the disease. Actor Alan Rickman died in 2016, five months after being diagnosed with the cancer.

Symptoms of pancreatic cancer may include jaundice, itchy skin, dark-colored urine, pale-colored stools, unexplained weight loss, fatigue and a high temperature or fever.

pancreatic cancerdaraxonrasib tabletcancer treatmentclinical trialtumor shrinkageCancer Research UKtargeted inhibitoradvanced cancersurvival ratechemotherapy
    আগামীর সময় ইপেপার
    শেয়ার করুন: